ArticleClinical, cosmetic and investigational dermatology2025
Successful Treatment of Delayed Onset Nodules After Dermal Fillers Injection with Abrocitinib: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
- Successful Treatment of Cutaneous Foreign Body Granuloma with JAK Inhibitor Abrocitinib and Prednisone: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Clinical updates of JAK inhibitors in cutaneous granulomatous diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed-onset nodules (DONs) are masses that occurs primarily at or near the injection site stemmed from the injection of dermal fillers. This term is descriptive and encompasses a range of potential underlying diagnoses, including product redistribution, delayed hypersensitivity reaction, biofilm, granuloma, among others. Addressing DONs can pose significant challenges, varying tremendously grounded in multiple factors such as whether the nodule is inflammatory, its timing of emergence, and the specific filler material utilized. In this context, we present the case of a 32-year-old woman who presented to the hospital with facial nodules persisting for one month. The patient was diagnosed with DONs (suspected foreign body granulomas) on the basis of her clinical presentation and laboratory test results. She was treated with abrocitinib, a Janus kinase (JAK) inhibitor, for four weeks, which resulted in the complete resolution of her rash. Subsequent follow-up visits confirmed no adverse effects or relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.